The convergence of artificial intelligence and biological engineering is ushering in a new era of drug design. On this episode of the AWS Health Innovation Podcast, Sanjit Misra speaks with Tharindi Hapuarachchi, VP of Platform Strategy & Operations at Generate:Biomedicines, about their groundbreaking work in generative biology. Through their innovative platform, they're revolutionizing how we design therapeutic proteins, bringing unprecedented speed and precision to drug development.

1. How did Tharindi's unique background prepare her for pioneering work in biotech?

• Her journey from mathematics to bioengineering provides the perfect blend of analytical thinking and biological understanding needed for modern therapeutic development. This interdisciplinary expertise enables her to bridge the gap between computational design and practical applications in medicine.

2. What makes Generate:Biomedicines' approach to protein design revolutionary?

• Their platform combines advanced machine learning with biological engineering in a novel "lab in the loop" system. This integration allows them to test millions of protein designs within weeks, dramatically accelerating the traditional drug discovery timeline.

3. How does Generate:Biomedicines maintain seamless translation from design to application?

• A 330-person team operates both computational models and wet labs under one roof, creating an integrated ecosystem where AI-designed proteins can be rapidly tested and validated for therapeutic use.

4. What real-world success demonstrates the platform's capabilities?

• Their COVID antibody development program showcases the platform's power, completing in just 17 months. The ability to simultaneously optimize multiple properties represents a significant advancement over traditional pharmaceutical development methods.

5. How does Generate:Biomedicines' infrastructure support rapid innovation?

• Their system combines proprietary protein databases with 24/7 automated laboratories, enabling continuous learning and iteration in the protein design process. This infrastructure creates a powerful feedback loop that enhances the platform's capabilities over time.

6. What potential impact could this technology have on healthcare accessibility?

• The platform aims to reduce development costs while accelerating therapeutic creation, potentially enabling more personalized treatments for underserved populations and improving access to breakthrough medicines.

Learn more about Generate:Biomedicines at generatebiomedicines.com

Get in touch with AWS here to learn how we can help your organization accelerate healthcare innovation.

Please take a moment and let us know what you think of the podcast, access our feedback survey here.